UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Circulation (New York, N.Y.), 2021-10, Vol.144 (16), p.1284-1294

2021

Link zum Volltext

Verfügbarkeit prüfen

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial

Thrombosis and haemostasis, 2011-04, Vol.105 (4), p.721

2011

Link zum Volltext

Verfügbarkeit prüfen

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

The New England journal of medicine, 2009-12, Vol.361 (24), p.2342-2352

2009

Link zum Volltext

Verfügbarkeit prüfen

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system

Thrombosis and haemostasis, 2015, Vol.114 (6), p.1290

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Journal of the American College of Cardiology, 2021-09, Vol.78 (13), p.1321-1332

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

European journal of heart failure, 2020-12, Vol.22 (12), p.2383-2392

2020

Link zum Volltext

Verfügbarkeit prüfen

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

The Lancet (British edition), 2007-09, Vol.370 (9591), p.949-956

2007

Link zum Volltext

Verfügbarkeit prüfen

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

The Journal of arthroplasty, 2009, Vol.24 (1), p.1-9

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

JACC. Heart failure, 2023-04, Vol.11 (4), p.407-417

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Nature Medicine, 2022-12, Vol.28 (12), p.2512-2520

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Circulation (New York, N.Y.), 2021-01, Vol.143 (4), p.310-321

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

European heart journal, 2022-02, Vol.43 (5), p.416-426

2022

Link zum Volltext

Verfügbarkeit prüfen

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

European heart journal, 2021-02, Vol.42 (6), p.671-680

2021

Link zum Volltext

Verfügbarkeit prüfen

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

European heart journal, 2021-11, Vol.42 (43), p.4442-4451

2021

Link zum Volltext

Verfügbarkeit prüfen

CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1656-1656

2017

Link zum Volltext

Verfügbarkeit prüfen

The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism After Major Orthopedic Surgery

The Journal of arthroplasty, 2008, Vol.23 (2), p.320-320

2008

Link zum Volltext

Verfügbarkeit prüfen

P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Heart & lung, 2021-07, Vol.50 (4), p.561-561

2021

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

Nature medicine, 2022-12, Vol.28 (12), p.2480-2481

2022

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin II, adhesion, and cardiac fibrosis

Cardiovascular research, 2000-05, Vol.46 (2), p.264-268

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract 18353: The Comparative Safety and Effectiveness of the Oral Anticoagulant (OAC) Dabigatran versus Warfarin Utilized in a Large Healthcare System in Non-valvular Atrial Fibrillation (NVAF) Patients

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

Current medical research and opinion, 2014-05, Vol.30 (5), p.795-804

2014

Link zum Volltext

Verfügbarkeit prüfen

Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart

Journal of the American College of Cardiology, 2004-05, Vol.43 (9), p.1698-1705

2004

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials

Thrombosis research, 2012-09, Vol.130 (3), p.396-402

2012

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Blood, 2011-11, Vol.118 (21), p.205-205

2011

Link zum Volltext

Verfügbarkeit prüfen

Human homologs of the Xenopus oocyte cortical granule lectin XL35

Glycobiology (Oxford), 2001-01, Vol.11 (1), p.65-73

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Humans
(21)
Cardiovascular System & Cardiology
(15)
Aged
(10)
Cardiac & Cardiovascular Systems
(10)
Heart Failure
(10)
Male
(10)
Middle Aged
(10)
Biological And Medical Sciences
(9)
Female
(9)
Life Sciences
(9)
Glucosides - Therapeutic Use
(8)
Heart Failure - Drug Therapy
(8)
Cardiology And Cardiovascular System
(7)
Human Health And Pathology
(7)
Peripheral Vascular Disease
(7)
Animals
(6)
Anticoagulants - Adverse Effects
(6)
Benzhydryl Compounds - Therapeutic Use
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME

The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism After Major Orthopedic Surgery

P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

Angiotensin II, adhesion, and cardiac fibrosis

Abstract 18353: The Comparative Safety and Effectiveness of the Oral Anticoagulant (OAC) Dabigatran versus Warfarin Utilized in a Large Healthcare System in Non-valvular Atrial Fibrillation (NVAF) Patients

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart

Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Human homologs of the Xenopus oocyte cortical granule lectin XL35

Suchergebnisse filtern